NSE filing, NSE: GKSL. Summary written from the filing by ALFA Finder's alert engine.
Gujarat Kidney and Super Speciality Ltd: key numbers
- Share price
- ₹159.98
- Market cap
- ₹1,261 Cr
- Revenue (annual)
- ₹82.01 Cr
- Net profit (annual)
- ₹15.50 Cr
- P/E (TTM)
- 79.7×Sector 53.8×
- Promoter holding
- 71.45%+0.00% QoQ
- FII holding
- 6.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gujarat Kidney and Super Speciality Ltd
All →Gujarat Kidney and Super Speciality Q2 FY27 Results: Net Profit ₹6.6 Cr, Up 127.6% YoY
Gujarat Kidney and Super Speciality Ltd reported revenue from operations of ₹38.1 Cr (+195.3% YoY) and net profit of ₹6.6 Cr (+127.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹6.6 Cr · +127.6% YoY
Gujarat Kidney and Super Speciality Board Meeting Date
Gujarat Kidney will hold a board meeting on 04 Nov 2026 to consider unaudited quarterly results. The trading window closes from 01 Oct 2026.
Gujarat Kidney and Super Speciality Other Announcement
This is a routine quarterly shareholding pattern disclosure for the period ended September 30, 2026, filed under SEBI Regulation 31.
Gujarat Kidney and Super Speciality Annual General Meeting
Gujarat Kidney and Super Speciality Limited held its 7th Annual General Meeting on September 28, 2026. Shareholders approved financial statements, director appointments, and various regulatory borrowing and investment limits.
Gujarat Kidney and Super Speciality Annual Report
Gujarat Kidney and Super Speciality Limited issued a corrigendum to its FY 2025-26 Annual Report. The update includes missing Secretarial Audit observations and management responses.
Gujarat Kidney and Super Speciality Annual General Meeting
Gujarat Kidney and Super Speciality Limited has issued a notice for its 7th Annual General Meeting scheduled for September 28, 2026. The meeting will address financial statements, director appointments, and related party transactions.
- Value
- ₹1.78 Cr
Other other announcement announcements
All →Transchem Other Announcement
Transchem's monitoring agency reports no deviation in warrant proceeds utilisation for the quarter ended September 2026. No material facts were flagged.
Archidply Industries Other Announcement
Archidply Industries disclosed that its RTA, KFin Technologies, is shifting its corporate office to Kokapet, Hyderabad from December 1, 2026. The registered office is unchanged and shareholders should update correspondence addresses.
KEI Industries Other Announcement
Designated person Jashobant Singha Ray pledged 1,500 KEI Industries shares. After the transaction, 10,000 of his 18,000 shares are pledged, with no cash consideration disclosed.
Kansai Nerolac Paints Other Announcement
Kansai Nerolac authorised Pravin Chaudhari, Yash Ahuja and Rukmini Subramanian to determine material events from 1 December 2026. It only lists KMP and contact details.
Glenmark Pharmaceuticals Other Announcement
Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.
Vineet Laboratories Other Announcement
Vineet Laboratories' board appointed SVRL & Co. as statutory auditors, subject to shareholder approval. The five-year term runs from the 10th AGM to the 16th AGM.